← Back to Search

Cholinesterase Inhibitor

treatment for Myasthenia Gravis

Phase 2

Waitlist Available

Research Sponsored by DAS-MG, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks

Awards & highlights

Study Summary

This trial is testing a new medication for myasthenia gravis, a disease that causes muscle weakness.

Eligible Conditions

Myasthenia Gravis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with change in the gastrointestinal (GI) side effects

Secondary outcome measures

Number of participants with change in Electrocardiography (ECG)

Number of participants with change in in clinical laboratory evaluations

Number of participants with change in in physical examine

+3 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: treatmentActive Control1 Intervention

ondansetron + pyridostigmine

Group II: PlaceboPlacebo Group1 Intervention

placebo+ pyridostigmine

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

DAS-MG, IncLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment in this trial still open to those seeking treatment?

"According to the latest data on clinicaltrials.gov, this investigation into new treatments is currently open for enrollment. The trial was initially published on April 8th 2021 and has had its last update on April 22nd 2022."

Answered by AI

How many participants is this clinical research accommodating?

"Affirmative, the clinicaltrials.gov website shows that this experiment is actively searching for participants. It was posted on April 8th 2021 and modified most recently on 4/22/2022. A total of 24 subjects are needed from 1 site to complete the trial."

Answered by AI

Has this therapeutic intervention been granted authorization by the FDA?

"The safety of this treatment is assessed as a 2, considering that it has only reached Phase 2. This means there are some data points confirming the intervention's security, but none yet to confirm its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

2021. "Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04226170.

All > Myasthenia Gravis